Intercontinental Exchange Inc. Common Stock vs Liquidia Corporation Common Stock — how do they compare? Intercontinental Exchange Inc. Common Stock trades at $156.56 (market cap $87.08B), while Liquidia Corporation Common Stock trades at $34.27 (market cap $3.04B). The key difference: Intercontinental Exchange Inc. Common Stock is far larger — about 28.6× Liquidia Corporation Common Stock's market cap, and Intercontinental Exchange Inc. Common Stock pays a 1.34% dividend while Liquidia Corporation Common Stock pays none. Which is the better fit depends on your goals.
| ICE | LQDA | |
|---|---|---|
Market Cap | $87.08B | $3.04B |
Volume | 3,543,870 | 21,111,778 |
Sector | Financials | Health |
52-Week High | $175.10 | $91.03 |
52-Week Low | $122.91 | $22.02 |
Enterprise Value | $104.98B | $2.94B |
Dividend Yield | 1.34% | — |
Typical Hold Time | — | 0 Days |
Signals from Pluang's Aura AI — not financial advice
Intercontinental Exchange (ICE) trades at $156.42, down 0.64% on the day, with strong technical momentum showing bullish moving averages and key support at $155. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $1.90 versus $1.84, maintaining a three-quarter beat streak. Revenue growth accelerated to $13.4 billion in 2026 with net profit margin expanding to 30.07%, supported by record trading volumes in key markets.
ICE presents a compelling investment case with 89% analyst buy ratings and a $183.89 consensus price target implying 17.6% upside. The exchange operator's diversified platform and recurring revenue model provide stability, though investors should monitor competitive pressures and market volatility impacts. Strong cash flow generation and institutional support reinforce the bullish outlook despite near-term technical overbought conditions.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Intercontinental Exchange provides technology and data services for financial institutions, corporations, and governments. Its businesses include exchanges and clearing, fixed-income data and analytics, and mortgage technology.
Read more on ICE →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →